icrf 198 has been researched along with mitoxantrone in 1 studies
Studies (icrf 198) | Trials (icrf 198) | Recent Studies (post-2010) (icrf 198) | Studies (mitoxantrone) | Trials (mitoxantrone) | Recent Studies (post-2010) (mitoxantrone) |
---|---|---|---|---|---|
24 | 0 | 4 | 4,555 | 1,042 | 1,004 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hasinoff, BB; Malisza, KL | 1 |
1 other study(ies) available for icrf 198 and mitoxantrone
Article | Year |
---|---|
Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
Topics: Aerobiosis; Antibiotics, Antineoplastic; Antioxidants; Chelating Agents; Doxorubicin; Electron Spin Resonance Spectroscopy; Ethylenediamines; Ferric Compounds; Ferrous Compounds; Glycine; Heart; Hydrolysis; Hydroxyl Radical; Mitoxantrone; Models, Chemical; Oxidation-Reduction; Razoxane | 1995 |